These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 28151736

  • 1. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
    Seinen ML, van Asseldonk DP, de Boer NK, Bouma G, van Nieuwkerk CM, Mulder CJ, Bloemena E, van Bodegraven AA.
    Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
    [Abstract] [Full Text] [Related]

  • 2. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
    van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.
    Inflamm Bowel Dis; 2016 Sep; 22(9):2112-20. PubMed ID: 27482972
    [Abstract] [Full Text] [Related]

  • 3. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO.
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
    [Abstract] [Full Text] [Related]

  • 4. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-Witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA.
    Scand J Gastroenterol; 2019 Jun; 54(6):753-760. PubMed ID: 31203688
    [Abstract] [Full Text] [Related]

  • 5. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
    De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA.
    Scand J Gastroenterol; 2008 Jun; 43(5):604-8. PubMed ID: 18415755
    [Abstract] [Full Text] [Related]

  • 6. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [Abstract] [Full Text] [Related]

  • 7. The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
    Gilissen LPL, Tajzai R, Romberg M, Pierik M, Stronkhorst A, Steenhuisen K, Van Bodegraven A, Daniels A, Wong D.
    Eur J Gastroenterol Hepatol; 2021 Dec 01; 33(1S Suppl 1):e102-e107. PubMed ID: 33136726
    [Abstract] [Full Text] [Related]

  • 8. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
    Kreijne JE, de Veer RC, de Boer NK, Dijkstra G, West R, Moorsel SAW, de Jong DJ, van der Woude CJ, de Vries AC, of the Dutch Initiative on Crohn, Colitis (ICC).
    Aliment Pharmacol Ther; 2019 Aug 01; 50(4):407-415. PubMed ID: 31359480
    [Abstract] [Full Text] [Related]

  • 9. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Simsek M, Meijer B, Ramsoekh D, Bouma G, van der Wouden EJ, den Hartog B, de Vries AC, Hoentjen F, Dijkstra G, de Boer SY, Jansen JM, van der Meulen AE, Beukers R, Brink MA, Steinhauser T, Oldenburg B, Gilissen LP, Naber TH, Verhagen MA, de Boer NKH, Mulder CJJ, Dutch Initiative on Crohn and Colitis (ICC).
    Clin Gastroenterol Hepatol; 2019 Feb 01; 17(3):568-570. PubMed ID: 29775790
    [Abstract] [Full Text] [Related]

  • 10. Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy.
    Simsek M, Seinen ML, de Boer NKH.
    Eur J Gastroenterol Hepatol; 2018 Oct 01; 30(10):1254-1255. PubMed ID: 30063483
    [No Abstract] [Full Text] [Related]

  • 11. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
    Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA.
    Inflamm Bowel Dis; 2013 Feb 01; 19(2):363-9. PubMed ID: 22605661
    [Abstract] [Full Text] [Related]

  • 12. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF.
    Gastroenterology; 2003 Aug 01; 125(2):298-303. PubMed ID: 12891528
    [Abstract] [Full Text] [Related]

  • 13. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
    Govani SM, Higgins PD.
    J Crohns Colitis; 2010 Oct 01; 4(4):444-9. PubMed ID: 21122542
    [Abstract] [Full Text] [Related]

  • 14. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
    Meijer B, Seinen ML, van Egmond R, Bouma G, Mulder CJJ, van Bodegraven AA, de Boer NKH.
    Inflamm Bowel Dis; 2017 Nov 01; 23(11):2011-2017. PubMed ID: 28617756
    [Abstract] [Full Text] [Related]

  • 15. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
    Seinen ML, van Asseldonk DP, de Boer NK, Losekoot N, Smid K, Mulder CJ, Bouma G, Peters GJ, van Bodegraven AA.
    J Crohns Colitis; 2013 Nov 01; 7(10):812-9. PubMed ID: 23317929
    [Abstract] [Full Text] [Related]

  • 16. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
    Curkovic I, Rentsch KM, Frei P, Fried M, Rogler G, Kullak-Ublick GA, Jetter A.
    Eur J Clin Pharmacol; 2013 Aug 01; 69(8):1521-31. PubMed ID: 23588559
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A.
    BMC Gastroenterol; 2020 Sep 11; 20(1):296. PubMed ID: 32917155
    [Abstract] [Full Text] [Related]

  • 18. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine.
    Seksik P, Mary JY, Beaugerie L, Lémann M, Colombel JF, Vernier-Massouille G, Cosnes J.
    Inflamm Bowel Dis; 2011 Feb 11; 17(2):565-72. PubMed ID: 20848502
    [Abstract] [Full Text] [Related]

  • 19. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
    Kiszka-Kanowitz M, Theede K, Nielsen AM.
    Ugeskr Laeger; 2014 May 26; 176(22):. PubMed ID: 25352005
    [Abstract] [Full Text] [Related]

  • 20. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
    Rahhal RM, Bishop WP.
    Inflamm Bowel Dis; 2008 Dec 26; 14(12):1678-82. PubMed ID: 18521913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.